{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:08:19Z","timestamp":1777918099456,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[1980,12,1]],"date-time":"1980-12-01T00:00:00Z","timestamp":344476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumori"],"published-print":{"date-parts":[[1980,12]]},"abstract":"<jats:p>Twenty-five patients with different metastatic tumors, and often with other diseases which may have further compromised their organic defenses (such as diabetes, anemia and neutropenia), had a simultaneous bacterial complication. This was regarded as documented (i.e., proved by positive culture) in 12 of 25 patients, and probable if subjective and objective symptoms, X-ray, laboratory tests and the clinical picture agreed with bacterial infection in progress, even though the culture was negative, in 13 of 25 patients. Antibiotic therapy with cefuroxime-tobramycin gave good results in 19 of 25 patients, i.e., in 10 of 12 with a documented infection and in 9 of 13 with a probable infection. Fever of unknow origin and urinary infections were the most responsive to the therapy. Three of 25 patients had nephrotoxicity, with a very small rise in BUN and creatinine, which was easily reversible. According to our experience, antibiotic therapy with cefuroxime-tobramycin would be useful in cancer patients with bacterial complications because of its effectiveness and tolerability.<\/jats:p>","DOI":"10.1177\/030089168006600612","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T12:23:52Z","timestamp":1523881432000},"page":"765-773","source":"Crossref","is-referenced-by-count":0,"title":["Cefuroxime-tobramycin Therapy in Cancer Patients with Bacterial Infections"],"prefix":"10.1177","volume":"66","author":[{"given":"Paolo","family":"Azzoni","sequence":"first","affiliation":[{"name":"Divisione Medica, Ospedale Orlandi, Bussolengo, Verona"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1980,12,1]]},"reference":[{"key":"bibr1-030089168006600612","first-page":"787","volume":"4","author":"Armstrong D.","year":"1971","journal-title":"Med. Clin. North Am."},{"key":"bibr2-030089168006600612","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-64-2-328"},{"key":"bibr3-030089168006600612","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197804)41:4<1610::AID-CNCR2820410452>3.0.CO;2-B"},{"key":"bibr4-030089168006600612","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.1.1.41"},{"key":"bibr5-030089168006600612","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197012172832507"},{"key":"bibr6-030089168006600612","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/122.5.419"},{"key":"bibr7-030089168006600612","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196410152711608"},{"key":"bibr8-030089168006600612","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(72)90036-9"},{"key":"bibr9-030089168006600612","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(73)90007-8"},{"key":"bibr10-030089168006600612","first-page":"445","volume-title":"In: I Tumori Infantili","author":"Klastersky J.","year":"1976"},{"key":"bibr11-030089168006600612","first-page":"674","volume":"27","author":"Mc Ripley R.T.","year":"1967","journal-title":"Cancer Res."},{"key":"bibr12-030089168006600612","first-page":"13","author":"Periti P.","year":"1978","journal-title":"Abstr. Anticipativi Glaxo"},{"key":"bibr13-030089168006600612","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197310)32:4<1007::AID-CNCR2820320437>3.0.CO;2-M"},{"key":"bibr14-030089168006600612","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-77-5-707"},{"key":"bibr15-030089168006600612","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(73)90106-0"},{"key":"bibr16-030089168006600612","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-197409000-00003"},{"key":"bibr17-030089168006600612","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)92825-8"},{"key":"bibr18-030089168006600612","first-page":"11","author":"Walker T.","year":"1978","journal-title":"Why cefuroxime? The first methoximine."}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030089168006600612","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030089168006600612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:30:45Z","timestamp":1777660245000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/030089168006600612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1980,12]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1980,12]]}},"alternative-id":["10.1177\/030089168006600612"],"URL":"https:\/\/doi.org\/10.1177\/030089168006600612","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[1980,12]]}}}